Guntram Schernthaner

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

L Rydén, Eberhard Standl, M. Bartnik et al. · European Heart Journal · 2006 · 1.7K citations · Full text

Medicine, Cardiology, Endocrinology +17

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

John B. Buse, Michael A. Nauck, Thomas Först et al. · The Lancet · 2012 · 563 citations

Medicine, Endocrinology, Pharmacotherapy +13

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

Guntram Schernthaner, Jorge Luiz Gross, Julio Rosenstock et al. · Diabetes Care · 2013 · 479 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke

Robert Wilcox, Marie‐Germaine Bousser, D. J. Betteridge et al. · Stroke · 2007 · 476 citations

Pharmacy, Pharmacology, Pharmacotherapy +17